Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Celldex issued a press release on August 6, 2026 announcing its financial results for the second quarter of 2026, including consolidated statements of operations and balance sheet data. The disclosure includes quarterly revenues ($22K), operating expenses ($80.6M), net loss ($73.5M), and loss per share ($0.94), along with cash position ($717.6M) and forward-looking guidance that cash is sufficient through 2028. This is a standard earnings release disclosure under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Corvus Pharmaceuticals' financial results for Q2 2026 (three and six months ended June 30, 2026), including net loss of $18.0 million for Q2 2026, R&D expenses of $16.0 million, and cash position of $215.2 million as of June 30, 2026. The press release is furnished as Exhibit 99.1 and filed under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes both financial results and a business update on clinical trial progress, which is typical for clinical-stage biopharmaceutical companies.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
AvePoint issued a press release on August 6, 2026 announcing its financial results for the second quarter ended June 30, 2026, disclosing Q2 2026 revenue of $124.5 million (22% YoY growth), SaaS revenue of $98.5 million (27% YoY growth), ARR of $465.1 million (27% YoY growth), and updated full-year 2026 guidance. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the standard format for earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Profound Medical's Q2 2026 financial results for the quarter ended June 30, 2026. The press release reports total revenue of $2.5 million (up 12% YoY, or 153% excluding shipment timing), gross margin of 78%, operating expenses declining 16%, and net loss improving 39% to $9.5 million. The company also reiterates full-year 2026 revenue guidance of $25.0 million. The filing includes condensed consolidated balance sheets and is furnished as Exhibit 99.1 to Item 2.02, which is the standard Item for results of operations and financial condition.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-08-06
EX-99.1
This is a press release disclosing Cellectis' financial results for the second quarter 2026 (six-month period ended June 30, 2026), including consolidated statements of financial position, operations, and per-share metrics. The document presents both interim financial statements and operational updates on clinical trials (lasme-cel, eti-cel), regulatory milestones (FDA RMAT designation), and cash position ($169 million). As a clinical-stage biotech company, these results and regulatory developments are material to investors assessing the registrant's progress and financial runway.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-06
This is a press release announcing Nova's second quarter 2026 financial results, including record quarterly revenue of $255.0 million (up 16% YoY), record GAAP net income of $75.0 million ($2.20 per diluted share), and record non-GAAP net income of $86.5 million ($2.51 per diluted share). The release includes detailed financial statements, management commentary, and forward guidance for Q3 2026. This is a classic earnings release disclosing quarterly results, material to investors assessing the registrant's financial performance and trajectory.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-08-06
EX-99
This exhibit is a press release announcing MIND CTI's second quarter 2026 financial results, including revenues of $4.6 million, operating income of $0.7 million, and net income of $0.8 million ($0.04 per share), along with six-month comparative results. The document includes condensed consolidated financial statements (income statement, balance sheet, and cash flow statement) and management commentary. While the exhibit also discloses two Nasdaq compliance notifications (minimum bid price deficiency and audit committee composition), the primary and dominant disclosure is the quarterly earnings announcement, which is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
PRA Group issued a press release on August 6, 2026 announcing its second quarter 2026 financial results, including net income of $58 million, diluted EPS of $1.51, total cash collections of $559 million (up 4%), and adjusted EBITDA of $1.4 billion (up 10%). The company also disclosed details of a webcast and conference call to discuss the Q2 2026 results.
View raw filing on EDGAR →
6-K
Earnings release
confidence 97%
filed 2026-08-06
EX-99.1
Amdocs Limited reported third quarter fiscal 2026 financial results with revenue of $1.175 billion (up 2.7% year-over-year), GAAP diluted EPS of $0.59, and non-GAAP diluted EPS of $1.84, along with updated guidance and management commentary on operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
LifeStance issued a press release on August 6, 2026 announcing Q2 2026 financial results, including revenue of $435.4 million (26% YoY growth), net income of $23.6 million (vs. prior-year loss of $3.8 million), and Adjusted EBITDA of $66.0 million, along with raised full-year 2026 guidance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
TTM Technologies disclosed second quarter 2026 financial results via press release attached as Exhibit 99.1, reporting net sales of $1.0 billion (up 37% year-over-year, an all-time quarterly record), GAAP net income of $83.0 million ($0.77 per diluted share), and non-GAAP net income of $106.9 million ($0.99 per diluted share, also an all-time quarterly record). The filing includes detailed financial statements, segment data, and forward guidance for Q3 and full-year 2026. This is a standard Item 2.02 earnings release disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
First Advantage issued a press release on August 6, 2026 announcing Q2 2026 financial results, with revenues of $448.8 million (14.9% YoY growth), net income of $16.9 million, and raised full-year 2026 guidance across multiple metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Generate Biomedicines issued a press release on August 6, 2026, reporting financial results for the quarter ended June 30, 2026, including revenue of $6.3 million, R&D expenses of $64.3 million, net loss of $67.3 million, and cash position of $457.4 million. The filing includes condensed consolidated balance sheets and statements of operations with comparative periods, which are hallmarks of a quarterly earnings release under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Geron Corporation issued a press release on August 5, 2026, announcing its financial results for the quarter ended June 30, 2026, including Q2 2026 net product revenue of $57.5 million, net loss of $16.7 million, and 2026 full-year financial guidance. The disclosure is a standard quarterly earnings announcement with detailed financial results and business highlights, filed under Item 2.02 with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
MidCap Financial Investment Corporation disclosed its quarterly financial results for the period ended June 30, 2026 via a press release furnished as Exhibit 99.1. The disclosure includes net investment income per share ($0.40), NAV per share ($13.37), portfolio activity, operating results, and other financial metrics typical of an earnings release. This is a standard Item 2.02 earnings disclosure for a BDC (Business Development Company) and is material to investors assessing the registrant's financial performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Targa Resources Corp. disclosed its financial results for the three and six months ended June 30, 2026, reporting net income of $765 million (up 22% year-over-year) and record adjusted EBITDA of $1,603 million (up 38%), along with updated full-year 2026 guidance and detailed segment performance analysis.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
GEO Group issued a press release on August 6, 2026, announcing second quarter 2026 financial results (revenues of $732.1 million, net income of $47.5 million), updated full-year 2026 guidance (revenues $2.95-$3.05 billion, net income $168-$175 million), and provided Q3 and Q4 2026 guidance. This is a standard earnings release disclosure under Item 2.02, material to investors assessing the company's financial performance and outlook.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Leggett & Platt issued a press release on August 6, 2026 announcing its financial results for the second quarter ending June 30, 2026, reporting Q2 sales of $1.0 billion (down 6% YoY), EPS of $0.33, and adjusted EPS of $0.39 (up $0.09 vs. prior year), along with segment-level results and withdrawal of forward guidance due to the pending Somnigroup merger.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
NexPoint Real Estate Finance issued a press release on August 6, 2026, announcing its financial results for the second quarter ended June 30, 2026. The disclosure reports net income attributable to common stockholders of $5.4 million ($0.29 per diluted share), cash available for distribution of $13.9 million ($0.58 per diluted common share), and provides third quarter 2026 guidance. This is a standard quarterly earnings release with detailed financial metrics and forward guidance, clearly falling under Item 2.02 (Results of Operations and Financial Condition).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Graham Corporation issued a press release on August 6, 2026, disclosing first quarter fiscal 2027 financial results, including record net sales of $71.3 million (up 29%), net income per diluted share of $0.33, and record backlog of $557.2 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Palladyne AI issued a press release announcing its financial results for Q2 2026 and the six months ended June 30, 2026, disclosing revenue of $5.8 million (470% YoY growth), an operating loss of $13.4 million, and a net loss of $0.27 per share, along with strategic highlights including new contract awards of $13.0 million and backlog of $24.6 million, with full-year 2026 guidance of $24-27 million in revenue.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
DNOW Inc. issued a press release on August 6, 2026 announcing second-quarter 2026 earnings results for the period ended June 30, 2026, including revenue of $1,307 million, adjusted EBITDA of $60 million, and net loss of $21 million. The filing explicitly states "DNOW Inc. issued a press release announcing earnings for the quarter ended June 30, 2026" and furnishes the earnings announcement as Exhibit 99.1, which is the standard disclosure mechanism for quarterly financial results under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
Evergy issued a press release on August 6, 2026, announcing second quarter 2026 financial results with GAAP EPS of $0.91 and adjusted EPS of $0.88, compared to prior-year results of $0.74 and $0.82 respectively. The company reaffirmed full-year 2026 adjusted EPS guidance of $4.14 to $4.34 and declared a dividend.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Liquidity Services' financial results for the fiscal quarter ended June 30, 2026. The press release (Exhibit 99.1) announces quarterly financial metrics including GMV of $453.0 million (up 10%), revenue of $129.6 million (up 8%), GAAP net income of $10.4 million (up 41%), and diluted EPS of $0.32 (up 39%), along with segment results and forward guidance for Q4-FY26. This is a standard Item 2.02 earnings disclosure that would materially affect a reasonable investor's assessment of the company's financial performance.
View raw filing on EDGAR →
6-K
Earnings release
confidence 98%
filed 2026-08-06
EX-99.2
This is a press release announcing Genius Sports' second quarter 2026 financial results, including revenue of $195.5 million (beating guidance of $185 million), net loss of $76.7 million, and adjusted EBITDA of $52.6 million (beating guidance of $45 million). The company also raised its full-year 2026 revenue and adjusted EBITDA guidance. The exhibit includes condensed consolidated financial statements, cash flow statements, and reconciliation tables typical of an earnings release.
View raw filing on EDGAR →
8-K
Earnings release
confidence 92%
filed 2026-08-06
Dana Incorporated disclosed its second-quarter 2026 financial results via a press release attached as Exhibit 99.1, reporting sales of $2.01 billion (up 4% YoY), adjusted EBITDA of $207 million with a 10.3% margin (up 270 basis points), and increased full-year guidance. The filing explicitly states "Dana Incorporated today issued a news release announcing its results for the quarter ended June 30, 2026" under Items 2.02 and 7.01, which is the standard disclosure mechanism for quarterly earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
TripAdvisor issued a press release on August 6, 2026 announcing preliminary financial results for Q2 and H1 2026, disclosing revenue of $441.9 million (down 7% YoY), net income of $22.8 million ($0.19 diluted EPS), and adjusted EBITDA of $76.4 million. The filing explicitly states this is an earnings announcement with the full press release furnished as Exhibit 99.1, which is the standard format for earnings releases under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Amylyx Pharmaceuticals issued a press release on August 6, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing R&D expenses ($23.8M), SG&A expenses ($21.9M), net loss ($43.4M or $0.39 per share), and cash position ($250.8M). The filing is made under Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Nexstar Media Group issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing record quarterly net revenue of $2.0 billion, net income of $113 million, and adjusted EBITDA of $633 million. This is a standard quarterly earnings release filed under Item 2.02 (Results of Operations and Financial Condition) with the press release attached as Exhibit 99.1, which is the typical disclosure mechanism for earnings announcements.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Monte Rosa Therapeutics announced its financial results for the quarter ended June 30, 2026, on August 6, 2026. The disclosure includes quarterly financial metrics (collaboration revenue of $9.0 million, R&D expenses of $48.0 million, G&A expenses of $10.1 million, net loss of $43.4 million) and cash position ($626.0 million), along with business highlights and clinical program updates. This is a standard quarterly earnings release furnished as Exhibit 99.1, typical of Item 2.02 disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Korro issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing cash position of $137.9 million, R&D expenses of $13.6 million, G&A expenses of $6.5 million, and a net loss of $18.9 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing quarterly financial results for Q2 2026 (quarter ended June 30, 2026) filed under Item 2.02 of Form 8-K. The press release reports revenues of $284 thousand, R&D expenses of $71.6 million, SG&A expenses of $55.0 million, and a net loss of $127.1 million, along with cash position of $981.5 million. The disclosure is material as it provides investors with the company's financial performance and cash runway information.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Vital Farms disclosed Q2 2026 financial results showing significant deterioration: net revenue of $166.0 million (down 10.1% year-over-year), gross margin collapsed from 38.9% to 6.6%, net loss of $31.1 million versus prior-year net income of $16.6 million, and adjusted EBITDA loss of $26.6 million, driven by industry-wide oversupply and pricing pressure. The company also revised full-year guidance and cancelled its stock repurchase program effective upon closing of the new credit facilities.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Cullinan Therapeutics' financial results for Q2 2026 and the six months ended June 30, 2026. The filing explicitly states "announced its financial results for the three and six months ended June 30, 2026" with a press release furnished as Exhibit 99.1. The exhibit contains consolidated statements of operations showing net loss of $53.7 million for Q2 2026 and $103.4 million for the six-month period, along with balance sheet data and detailed operating expense breakdowns. This is a material disclosure affecting investor assessment of the company's financial condition and operational performance.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Commerce.com issued a press release on August 6, 2026 announcing financial results for the second quarter and six months ended June 30, 2026. The disclosure includes key financial metrics (total revenue of $84.5 million, GAAP net income of $1.1 million, ARR of $360.5 million), operational highlights, and forward guidance for Q3 and full-year 2026. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02, which is the designated Item for results of operations and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Vistance Networks issued a press release on August 6, 2026 disclosing its financial results for the second quarter of 2026, including net sales of $319.6 million, GAAP income from continuing operations of $26.1 million, and non-GAAP adjusted EBITDA of $35.8 million. The press release is attached as Exhibit 99.1 and the company will host an earnings call to discuss these results, which is the standard format for quarterly earnings disclosures under Item 2.02.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Scholar Rock issued a press release on August 6, 2026 announcing its financial and operating results for the quarter ended June 30, 2026, including net loss of $109.9 million, R&D and G&A expenses, cash position of $492.1 million, and weighted average shares outstanding. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
REGENXBIO issued a press release on August 6, 2026 disclosing its financial results and operational highlights for the quarter ended June 30, 2026. The disclosure includes detailed financial statements (balance sheet, revenues, R&D and G&A expenses, net income), cash position analysis, and forward-looking guidance on cash runway into Q4 2027. This is a standard quarterly earnings release furnished under Item 2.02, with the press release attached as Exhibit 99.1.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-08-06
Item 2.02
FrontView REIT issued a press release on August 6, 2026 announcing second quarter 2026 financial results, including net income of $1.5 million ($0.03 per share), FFO of $7.2 million ($0.26 per share), and AFFO of $9.4 million ($0.33 per share), along with raised 2026 guidance for AFFO per share of $1.32–$1.34 and net investment guidance of $120.0 million.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release disclosing Nuvation Bio's Q2 2026 financial results, including $31.7 million in total revenue ($23.2 million in net product revenue for IBTROZI), R&D expenses of $30.7 million, SG&A expenses of $42.6 million, and a net loss of $62.8 million. The press release was issued on August 6, 2026, and is furnished as Exhibit 99.1 to the 8-K under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Climb Bio issued a press release on August 6, 2026 announcing financial results for the quarter ended June 30, 2026, including condensed consolidated balance sheets and statements of operations. The disclosure includes cash position ($239.2 million), R&D expenses ($9.7 million), G&A expenses ($5.6 million), net loss ($13.5 million), and net loss per share ($0.18), along with business updates on clinical pipeline progress. This is a standard quarterly earnings release with financial statements attached as Exhibit 99.1, typical of Item 2.02 disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-08-06
Item 2.02
PepGen disclosed Q2 2026 financial results via press release, reporting a net loss of $17.8 million (improved from $23.1 million in Q2 2025), R&D expenses of $12.5 million, and a cash position of $117.2 million, along with condensed consolidated financial statements and per-share metrics.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Lantheus announced via press release its financial results for the three and six months ended June 30, 2026, disclosing worldwide revenue of $388.2 million, GAAP fully diluted EPS of $1.11, and adjusted fully diluted EPS of $1.55. The Item 2.02 disclosure and attached Exhibit 99.1 press release are the classic format for earnings announcements. While the filing also mentions the pending Curium merger, the primary Item 2.02 content is the quarterly financial results disclosure.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
This is a quarterly earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The disclosure includes consolidated statements of operations showing net loss of $106.6 million for Q2 2026, balance sheet data, and business updates on clinical programs (lonvo-z Phase 3 positive results, nex-z enrollment progress). The press release is furnished as Exhibit 99.1 and contains standard financial metrics and operational highlights typical of an earnings announcement.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Cars.com Inc. issued a press release on August 6, 2026 announcing its financial results for the quarter ended June 30, 2026, disclosing revenue of $179.9 million (up 1% YoY), net income of $14.3 million (up 103% YoY), and Adjusted EBITDA of $53.0 million (up 4% YoY). The filing explicitly states this is furnished as Exhibit 99.1 under Item 2.02 (Results of Operations and Financial Condition), which is the standard Item for earnings releases. The disclosure includes detailed financial highlights, operational metrics, cash flow data, and forward guidance for Q3 and full-year 2026.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
Agenus announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure reports Q2 2026 revenue of $34.5 million (up from $25.7 million year-over-year), including $6.4 million in pre-commercial product revenue and $28.1 million in non-cash royalty revenue. This is a standard quarterly earnings release under Item 2.02, disclosing results of operations and financial condition.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release announces second quarter 2026 financial results, including net income of $2.6 million ($0.10/share), revenues of $17.4 million, and Adjusted EBITDA of $8.4 million, with detailed segment performance and forward guidance. The filing includes consolidated balance sheets and statements of operations, which are typical of quarterly earnings disclosures.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-08-06
Item 2.02
Radian Group Inc. issued a news release on August 5, 2026, announcing its financial results for the quarter ended June 30, 2026, disclosing net income from continuing operations of $118 million ($0.87 per diluted share) and adjusted diluted net operating income per share of $1.14. The filing explicitly states this is Item 2.02 (Results of Operations and Financial Condition) with the press release furnished as Exhibit 99.1, which is the standard format for quarterly earnings releases.
View raw filing on EDGAR →
8-K
Earnings release
confidence 94%
filed 2026-08-06
Item 2.02
MBX Biosciences announced Q2 2026 financial results via press release, reporting R&D expenses of $31.0M (vs. $17.7M YoY), G&A expenses of $9.9M (vs. $4.1M YoY), net loss of $37.1M (vs. $19.4M YoY), and cash position of $418.6M expected to fund operations into 2029.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-08-06
Item 2.02
ALX Oncology issued a press release on August 6, 2026, announcing its financial results for the second quarter ended June 30, 2026, including consolidated statements of operations, balance sheet data, and per-share metrics. The disclosure includes GAAP net loss of ($17.971) million and non-GAAP net loss of ($14.310) million for Q2 2026, along with cash position of $153.4 million and detailed operating expense breakdowns. This is a standard quarterly earnings release furnished as Exhibit 99.1 under Item 2.02.
View raw filing on EDGAR →